AZN ASTRAZENECA PLC IFRS
Pharmaceutical Preparations · NYSE · SEC CIK 901832 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY8.6%
TTM net income YoY45.3%
TTM EPS YoY45.3%
Revenue 3-yr CAGR9.8%
Net income 3-yr CAGR46.0%
Margins
Gross margin81.9%
Operating margin23.4%
Net margin17.4%
FCF margin20.0%
EBITDA margin—
Returns
ROE22.9%
ROA9.4%
ROIC (approx.)16.8%
Asset turnover0.54x
Leverage & solvency
Liabilities / assets57.3%
Debt / equity0.57x
Current ratio0.94x
Interest coverage8.11x
Cash quality & payout
Operating cash flow / net income1.43x
Accruals ratio-4.0%
Payout ratio48.6%
Capex / revenue4.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $58.74B | $54.07B |
| Cost of revenue | $10.63B | $10.21B |
| Gross profit | $48.11B | $43.87B |
| R&D expense | $14.23B | $13.58B |
| SG&A expense | $19.93B | $19.98B |
| Operating income | $13.74B | $10.00B |
| Interest expense | $1.69B | $1.74B |
| Pretax income | $12.40B | $8.69B |
| Income tax | $2.17B | $1.65B |
| Net income | $10.22B | $7.04B |
| EPS (basic) | 6.60 | 4.54 |
| EPS (diluted) | 6.54 | 4.50 |
| Dividends declared per share | 3.13 | 2.97 |
| Weighted avg. shares (diluted) | 1.56B | 1.56B |
| Balance sheet | ||
| Cash & equivalents | $5.71B | $5.49B |
| Short-term investments | $30.00M | $166.00M |
| Receivables | $15.18B | $12.97B |
| Inventory | $6.56B | $5.29B |
| Current assets | $28.72B | $25.83B |
| PP&E, netmay include right-of-use assets (IFRS) | $12.96B | $10.25B |
| Goodwill | $21.24B | $21.02B |
| Intangibles | $37.85B | $37.18B |
| Total assets | $114.07B | $104.03B |
| Current liabilities | $30.62B | $27.87B |
| Short-term debt | $3.10B | $2.34B |
| Long-term debt | $24.71B | $26.51B |
| Total debt | $27.82B | $28.84B |
| Total liabilities | $65.36B | $63.16B |
| Shareholders' equity | $48.67B | $40.79B |
| Net debt | $22.11B | $23.36B |
| Cash flow statement | ||
| Operating cash flow | $14.57B | $11.86B |
| Capital expenditure | $2.81B | $1.92B |
| Free cash flow | $11.77B | $9.94B |
| Investing cash flow | -$6.81B | -$7.98B |
| Financing cash flow | -$7.54B | -$4.00B |
| Stock-based compensation | $719.00M | $660.00M |
| Dividends paid | $4.97B | $4.63B |
| Share buybacks | $521.00M | $81.00M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.